{
    "clinical_study": {
        "@rank": "102570", 
        "arm_group": {
            "arm_group_label": "Ibuprofen Cream (SST-0225)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate how Ibuprofen Cream (SST-0225) is absorbed and\n      eliminated by the body under defined maximum dosing conditions and to evaluate the safety\n      under these conditions."
        }, 
        "brief_title": "Open-Label, Maximum-Dose Pharmacokinetic Study of 7.5% Ibuprofen Cream (SST-0225) in Healthy Adults", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed consent form\n\n          -  Men, women, 18 to 55 years\n\n          -  Females must not be pregnant or plan to become pregnant\n\n          -  BMI 18 to 30 kg/m2\n\n          -  Past or non-smoker\n\n          -  High probability of compliance with completion of study\n\n          -  Healthy as determined by investigator based on medical history, physical exam,\n             clinical laboratory tests, vital sign measurements, ECGs\n\n        Exclusion Criteria:\n\n          -  Presence or history of disorder that could interfere with completion of study\n\n          -  Unstable medical condition\n\n          -  Surgical or medical condition that may interfere with absorption, distribution,\n             metabolism or excretion of test drug\n\n          -  Positive Hep B, Hep C and/or HIV test\n\n          -  Positive urine drug screen\n\n          -  Any history of skin disorders, including psoriasis, eczema, tattoos, significant\n             scarring, healing wounds, skin lesions on knees or elbows\n\n          -  Significant disease\n\n          -  Any clinically important deviation from normal limits in physical exam, vital sign\n             measurements, 12 lead ECG, clinical laboratory test\n\n          -  History of drug abuse with 1 year\n\n          -  History of alcoholism with 1 year\n\n          -  Use of prescription medications or ibuprofen within 30 days of Day 1, use of OTC\n             drugs, herbal supplements and vitamins within 14 days of Day 1.\n\n          -  Use of investigational drug within 30 day of Day 1\n\n          -  Acute disease state within 7 days of Day 1\n\n          -  Consumption of grapefruit or grapefruit containing products within 72 hours of Day 1\n\n          -  Tobacco use/caffeine use within 48 hours of Day 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986660", 
            "org_study_id": "SST0225-US-011-001"
        }, 
        "intervention": {
            "arm_group_label": "Ibuprofen Cream (SST-0225)", 
            "intervention_name": "Ibuprofen Cream (SST-0225)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ibuprofen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Pharmacokinetic Study", 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York"
                }, 
                "name": "SST Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Cmax, Tmax, Trough Concentrations Days 2 to 8, AUC 0-24, Steady State, T1/2", 
            "safety_issue": "No", 
            "time_frame": "9 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986660"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical laboratory change from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Modified Berger Bowman Skin Assessment", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Vital Signs", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Adverse Events", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }
        ], 
        "source": "Strategic Science & Technologies, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Strategic Science & Technologies, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}